GlobeNewswire Inc | Dec 29, 2021 04:05PM EST

December 29, 2021

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 11, 2022, at 7:30 a.m. Eastern Standard Time.

A live and archived webcast of the presentation will be available on Investors section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonxs Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a breakthrough device. The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx, Chartis, StratX, and Zephyr are registered trademarks of Pulmonx Corporation.

ContactBrian JohnstonGilmartin Groupinvestors@pulmonx.com